Home Semiconductor & Electronics Electronic Components Ankylosing Spondylitis Market

Ankylosing Spondylitis Market Size, Share & Trends Analysis Report By Drug Class (Non-Steroidal Anti-Inflammatory Drug (NSAID), Other Drug Classes), By Disease Stage (Early-Stage Ankylosing Spondylitis, Moderate Ankylosing Spondylitis, Severe / Advanced Ankylosing Spondylitis), By Diagnostic Method (MRI, X-Ray Radiography, Blood Biomarkers (CRP/ESR), HLA-B27 Genetic Testing, Digital Spine Monitoring Tools), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: December 15, 2025 | Author: Debashree B | Format: | Report Code: SR7560DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Ankylosing Spondylitis Market, By Drug Class 2022-2034 (USD MILLION/ Units)
    1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
      1. TNF Inhibitors
      2. Humira
      3. Simponi
      4. Remicade
      5. Enbrel
      6. Cimzia
      7. Other TNF Inhibitors
    2. Other Drug Classes
  2. Ankylosing Spondylitis Market, By Disease Stage 2022-2034 (USD MILLION/ Units)
    1. Early-Stage Ankylosing Spondylitis
    2. Moderate Ankylosing Spondylitis
    3. Severe / Advanced Ankylosing Spondylitis
  3. Ankylosing Spondylitis Market, By Diagnostic Method 2022-2034 (USD MILLION/ Units)
    1. MRI
    2. X-Ray Radiography
    3. Blood Biomarkers (CRP/ESR)
    4. HLA-B27 Genetic Testing
    5. Digital Spine Monitoring Tools
  4. Ankylosing Spondylitis Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Hospital Pharmacy
    2. Retail Pharmacy
    3. Others
  5. Regional Ankylosing Spondylitis Market
    1. North America
      1. North America Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
          1. TNF Inhibitors
          2. Humira
          3. Simponi
          4. Remicade
          5. Enbrel
          6. Cimzia
          7. Other TNF Inhibitors
        2. Other Drug Classes
      2. North America Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
        1. Early-Stage Ankylosing Spondylitis
        2. Moderate Ankylosing Spondylitis
        3. Severe / Advanced Ankylosing Spondylitis
      3. North America Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
        1. MRI
        2. X-Ray Radiography
        3. Blood Biomarkers (CRP/ESR)
        4. HLA-B27 Genetic Testing
        5. Digital Spine Monitoring Tools
      4. North America Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Others
      5. U.S. Ankylosing Spondylitis Market
        1. U.S. Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. U.S. Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. U.S. Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. U.S. Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      6. Canada Ankylosing Spondylitis Market
        1. Canada Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. Canada Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. Canada Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. Canada Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
    2. Europe
      1. Europe Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
          1. TNF Inhibitors
          2. Humira
          3. Simponi
          4. Remicade
          5. Enbrel
          6. Cimzia
          7. Other TNF Inhibitors
        2. Other Drug Classes
      2. Europe Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
        1. Early-Stage Ankylosing Spondylitis
        2. Moderate Ankylosing Spondylitis
        3. Severe / Advanced Ankylosing Spondylitis
      3. Europe Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
        1. MRI
        2. X-Ray Radiography
        3. Blood Biomarkers (CRP/ESR)
        4. HLA-B27 Genetic Testing
        5. Digital Spine Monitoring Tools
      4. Europe Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Others
      5. U.K. Ankylosing Spondylitis Market
        1. U.K. Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. U.K. Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. U.K. Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. U.K. Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      6. Germany Ankylosing Spondylitis Market
        1. Germany Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. Germany Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. Germany Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. Germany Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      7. France Ankylosing Spondylitis Market
        1. France Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. France Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. France Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. France Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      8. Spain Ankylosing Spondylitis Market
        1. Spain Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. Spain Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. Spain Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. Spain Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      9. Italy Ankylosing Spondylitis Market
        1. Italy Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. Italy Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. Italy Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. Italy Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      10. Russia Ankylosing Spondylitis Market
        1. Russia Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. Russia Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. Russia Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. Russia Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      11. Nordic Ankylosing Spondylitis Market
        1. Nordic Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. Nordic Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. Nordic Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. Nordic Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      12. Benelux Ankylosing Spondylitis Market
        1. Benelux Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. Benelux Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. Benelux Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. Benelux Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      13. Rest of Europe Ankylosing Spondylitis Market
        1. Rest of Europe Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. Rest of Europe Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. Rest of Europe Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. Rest of Europe Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
    3. APAC
      1. APAC Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
          1. TNF Inhibitors
          2. Humira
          3. Simponi
          4. Remicade
          5. Enbrel
          6. Cimzia
          7. Other TNF Inhibitors
        2. Other Drug Classes
      2. APAC Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
        1. Early-Stage Ankylosing Spondylitis
        2. Moderate Ankylosing Spondylitis
        3. Severe / Advanced Ankylosing Spondylitis
      3. APAC Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
        1. MRI
        2. X-Ray Radiography
        3. Blood Biomarkers (CRP/ESR)
        4. HLA-B27 Genetic Testing
        5. Digital Spine Monitoring Tools
      4. APAC Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Others
      5. China Ankylosing Spondylitis Market
        1. China Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. China Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. China Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. China Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      6. Korea Ankylosing Spondylitis Market
        1. Korea Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. Korea Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. Korea Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. Korea Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      7. Japan Ankylosing Spondylitis Market
        1. Japan Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. Japan Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. Japan Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. Japan Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      8. India Ankylosing Spondylitis Market
        1. India Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. India Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. India Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. India Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      9. Australia Ankylosing Spondylitis Market
        1. Australia Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. Australia Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. Australia Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. Australia Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      10. Taiwan Ankylosing Spondylitis Market
        1. Taiwan Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. Taiwan Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. Taiwan Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. Taiwan Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      11. South East Asia Ankylosing Spondylitis Market
        1. South East Asia Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. South East Asia Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. South East Asia Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. South East Asia Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      12. Rest of Asia-Pacific Ankylosing Spondylitis Market
        1. Rest of Asia-Pacific Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. Rest of Asia-Pacific Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. Rest of Asia-Pacific Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. Rest of Asia-Pacific Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
    4. Middle East and Africa
      1. Middle East and Africa Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
          1. TNF Inhibitors
          2. Humira
          3. Simponi
          4. Remicade
          5. Enbrel
          6. Cimzia
          7. Other TNF Inhibitors
        2. Other Drug Classes
      2. Middle East and Africa Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
        1. Early-Stage Ankylosing Spondylitis
        2. Moderate Ankylosing Spondylitis
        3. Severe / Advanced Ankylosing Spondylitis
      3. Middle East and Africa Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
        1. MRI
        2. X-Ray Radiography
        3. Blood Biomarkers (CRP/ESR)
        4. HLA-B27 Genetic Testing
        5. Digital Spine Monitoring Tools
      4. Middle East and Africa Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Others
      5. UAE Ankylosing Spondylitis Market
        1. UAE Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. UAE Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. UAE Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. UAE Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      6. Turkey Ankylosing Spondylitis Market
        1. Turkey Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. Turkey Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. Turkey Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. Turkey Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      7. Saudi Arabia Ankylosing Spondylitis Market
        1. Saudi Arabia Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. Saudi Arabia Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. Saudi Arabia Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. Saudi Arabia Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      8. South Africa Ankylosing Spondylitis Market
        1. South Africa Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. South Africa Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. South Africa Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. South Africa Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      9. Egypt Ankylosing Spondylitis Market
        1. Egypt Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. Egypt Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. Egypt Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. Egypt Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      10. Nigeria Ankylosing Spondylitis Market
        1. Nigeria Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. Nigeria Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. Nigeria Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. Nigeria Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      11. Rest of MEA Ankylosing Spondylitis Market
        1. Rest of MEA Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. Rest of MEA Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. Rest of MEA Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. Rest of MEA Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
    5. LATAM
      1. LATAM Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
          1. TNF Inhibitors
          2. Humira
          3. Simponi
          4. Remicade
          5. Enbrel
          6. Cimzia
          7. Other TNF Inhibitors
        2. Other Drug Classes
      2. LATAM Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
        1. Early-Stage Ankylosing Spondylitis
        2. Moderate Ankylosing Spondylitis
        3. Severe / Advanced Ankylosing Spondylitis
      3. LATAM Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
        1. MRI
        2. X-Ray Radiography
        3. Blood Biomarkers (CRP/ESR)
        4. HLA-B27 Genetic Testing
        5. Digital Spine Monitoring Tools
      4. LATAM Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Others
      5. Brazil Ankylosing Spondylitis Market
        1. Brazil Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. Brazil Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. Brazil Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. Brazil Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      6. Mexico Ankylosing Spondylitis Market
        1. Mexico Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. Mexico Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. Mexico Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. Mexico Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      7. Argentina Ankylosing Spondylitis Market
        1. Argentina Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. Argentina Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. Argentina Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. Argentina Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      8. Chile Ankylosing Spondylitis Market
        1. Chile Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. Chile Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. Chile Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. Chile Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      9. Colombia Ankylosing Spondylitis Market
        1. Colombia Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. Colombia Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. Colombia Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. Colombia Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
      10. Rest of LATAM Ankylosing Spondylitis Market
        1. Rest of LATAM Ankylosing Spondylitis Market By Drug Class 2022-2034 (USD MILLION/ Units)
          1. Non-Steroidal Anti-Inflammatory Drug (NSAID)
            1. TNF Inhibitors
            2. Humira
            3. Simponi
            4. Remicade
            5. Enbrel
            6. Cimzia
            7. Other TNF Inhibitors
          2. Other Drug Classes
        2. Rest of LATAM Ankylosing Spondylitis Market By Disease Stage 2022-2034 (USD MILLION/ Units)
          1. Early-Stage Ankylosing Spondylitis
          2. Moderate Ankylosing Spondylitis
          3. Severe / Advanced Ankylosing Spondylitis
        3. Rest of LATAM Ankylosing Spondylitis Market By Diagnostic Method 2022-2034 (USD MILLION/ Units)
          1. MRI
          2. X-Ray Radiography
          3. Blood Biomarkers (CRP/ESR)
          4. HLA-B27 Genetic Testing
          5. Digital Spine Monitoring Tools
        4. Rest of LATAM Ankylosing Spondylitis Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
          1. Hospital Pharmacy
          2. Retail Pharmacy
          3. Others
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.